Table 1 Patient and tumor characteristics (Total n = 74)

Mean

59.6

61.7

Range

18–87

36–81

Sex

Female

36 (48.6%)

18 (46.2%)

Male

38 (51.4%)

21 (53.8%)

Tumor size

⩽ 5 cm (T1)

13 (17.6%)

4 (10.3%)

 > 5 cm (T2)

61 (82.4%)

35 (89.7%)

Mean tumor size (cm)

9.9 (± 5.5)

10.9 (± 5.9)

Tumor depth to superficial fascia

Superficial (Ta)

13 (17.6%)

5 (12.9%)

Deep (Tb)

61 (82.4%)

34 (87.1%)

Tumor malignancy grade

Grade I

2 (2.7%)

0 (0%)

Grade II

29 (39.2%)

16 (41.0%)

Grade III

41 (55.4%)

22 (56.4%)

Undetermined

2 (2.7%)

1 (2.6%)

Number of high-risk features

3

49 (66.2%)

29 (74.3%)

2

18 (24.3%)

8 (20.5%)

1

5 (6.8%)

1 (2.6%)

Missing data

2 (2.7%)

1 (2.6%)

Surgical margin status

R0

56 (75.7%)

30 (76.9%)

R1

16 (21.6%)

8 (20. 5%)

R2

2 (2.7%)

1 (2.6%)

Histology

Undifferentiated pleomorphic sarcoma

25 (33.8%)

Myxofibrosarcoma

9 (12.2%)

Liposarcoma

8 (10.8%)

Leiomyosarcoma

6 (8.1%)

Synovial sarcoma

5 (6.8%)

Other

21 (28.4%)

Histology (lower extremity)

Undifferentiated pleomorphic sarcoma

12 (30.8%)

Liposarcoma

5 (12.9%)

Synovial sarcoma

4 (10.1%)

Extrasceletal myxoid chondrosarcoma

3 (7.7%)

Other

15 (38.5%)

Therapy characteristics

Whole cohort

Lower extremity

Neoadjuvant radiotherapy

44 (59.5%)

24 (61.5%)

Adjuvant radiotherapy

30 (40.5%)

15 (38.5%)

Concomitant ifosfamide

43 (58.1%)

26 (66.7%)

No concomitant ifosfamide

31 (41.9%)

13 (33.3%)

Concomitant hyperthermia

42 (56.8%)

23 (59.0%)

No concomitant hyperthermia

32 (43.2%)

16 (41.0%)

Sequential chemotherapy

28 (37.8%)

16 (41.0%)

No sequential chemotherapy

46 (62.2%)

23 (59.0%)

3DCRT

56 (75.7%)

32 (82.1%)

IMRT

18 (24.3%)

7 (17.9%)